Blog
RSS FeedPosted by Michael Wonder on 27 Apr 2020
ICER releases evidence report on treatments for cystic fibrosis
27 April 2020 - Evidence on Trikafta provides high confidence of a substantial net health benefit for patients; additional benefits accrue ...
Posted by Michael Wonder on 23 Apr 2020
ICER Appoints Jon Campbell as Senior Vice President for Health Economics
23 April 2020 - In September, Jonathan D. Campbell, PhD, will become Senior Vice President for Health Economics at the Institute ...
Posted by Michael Wonder on 17 Apr 2020
America can afford a world class health care system. Why don’t we have one?
14 April 2020 - In March, Congress passed a coronavirus bill including $3.1 billion to develop and produce drugs and ...
Posted by Michael Wonder on 16 Apr 2020
ICER Appoints Yvette Venable as Vice President of Patient Engagement
16 April 2020 - The Institute for Clinical and Economic Review has announced the appointment of Yvette Venable as the organisation’s ...
Posted by Michael Wonder on 19 Mar 2020
Getting value right: the case for indirect benefits
19 March 2020 - According to the most recent estimates from the Centers for Medicare and Medicaid Services Office of the ...
Posted by Michael Wonder on 19 Mar 2020
ICER releases draft evidence report on obeticholic acid for non-alcoholic steatohepatitis
19 March 2020 - Public comment period on preliminary draft now open until 24 June 2020; requests to make oral comment ...
Posted by Michael Wonder on 18 Mar 2020
ICER indefinitely postpones public meetings for sickle cell disease and cystic fibrosis; expands other assessment timelines up to three months
18 March 2020 - Updated schedules are intended to enable participating clinical experts and patient advocates to focus on caring for ...
Posted by Michael Wonder on 15 Mar 2020
ICER posts draft scoping documents on bladder cancer and digital apps for opioid use disorder
13 March 2020 - Documents open to public comment until 2 April 2020. ...
Posted by Michael Wonder on 13 Mar 2020
ICER releases evidence report on treatments for sickle cell disease
12 March 2020 - Three new treatments use different mechanisms to improve patient outcomes, offering important options for patients. ...
Posted by Michael Wonder on 03 Mar 2020
ICER to postpone assessment of gene therapy for beta thalassemia
3 March 2020 - Due to delay in regulatory submission, ICER will reinitiate assessment at a future date — ...
Posted by Michael Wonder on 25 Feb 2020
ICER issues final report and policy recommendations on acute treatments for migraine
25 February 2020 - Evidence on new agents lasmiditan, ubrogepant, and rimegepant judged inadequate to demonstrate superiority over more affordable triptans. ...
Posted by Michael Wonder on 24 Feb 2020
Drug pricing review group signs deal with Aetion for patient data
24 February 2020 - The Institute for Clinical and Economic Review (ICER), a small but influential Boston-based research group, has ...
Posted by Michael Wonder on 24 Feb 2020
ICER and Aetion partner to develop real-world evidence for value assessment of treatments
24 February 2020 - ICER adopts Aetion’s Real-World Evidence Platform — advancing standards for the use of transparent, replicable real-world ...
Posted by Michael Wonder on 24 Feb 2020
ICER to assess evidence on supervised injection facilities and digital apps for opioid use disorder
21 February 2020 - ICER expands its reviews in area of ongoing public health crisis related to opioid addiction. ...
Posted by Michael Wonder on 20 Feb 2020
ICER to assess treatments for bladder cancer
20 February 2020 - Report will be subject of a Midwest CEPAC meeting in September 2020; open Input now being ...